Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide production

The mammalian target of rapamycin (mTOR) inhibiting drug rapamycin (Sirolimus) has severe side effects in patients including hyperlipidemia, an established risk factor for atherosclerosis. Recently, it was shown that rapamycin decreases hepatic LDL receptor (LDL-R) expression, which likely contribut...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Biochim Biophys Acta Mol Cell Biol Lipids
Autors principals: Fruhwürth, Stefanie, Krieger, Sigurd, Winter, Katharina, Rosner, Margit, Mikula, Mario, Weichhart, Thomas, Bittman, Robert, Hengstschläger, Markus, Stangl, Herbert
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6487575/
https://ncbi.nlm.nih.gov/pubmed/24713582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbalip.2014.03.014
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars